CAMP4 THERAPEUTICS CORPORATION CAMP
Set alert
3.96 USD +0.06 +1.54%
At close · Oct 30
3.96 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
3.78 Day range 4.00
2.90 52-week range 7.13
- YTD
- -35.40%
- 1 year
- -1.74%
- Open
- 3.86
- Prev close
- 3.90
- Mkt cap
- 248.50M
- Vol
- 138.00K
- Avg vol
- 264.01K
- EPS
- -2.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.78
- High
- 4.00
- Forward P/E
- -2.52
- Beta
- 0.00
- Short ratio
- 2.72
- Inst. own
- 42.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jul 8, 2024
- 50-d avg
- 8.46
- 200-d avg
- 8.46
- 1y target
- 19.91
2Y chart
Events in this range
- Nov 5, 2024Rating: Piper Sandler · — → Overweight
- Nov 5, 2024Rating: JP Morgan · — → Overweight
- Nov 5, 2024Rating: Leerink Partners · — → Outperform
- Nov 5, 2024Rating: William Blair · — → Outperform
Signals (116)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 7, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 4, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| SMA: Bullish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 6, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 2 months ago |
| RSI: Oversold | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 18, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | Jun 10, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 29, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 8, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| SMA: Bearish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 9, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 6 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| RSI: Oversold | Jan 26, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 26, 2025 | 10 months ago |
| RSI: Overbought | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 26, 2025 | 11 months ago |
| SMA: Bearish | Nov 21, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 13, 2025 | 11 months ago |
| MACD: Buy Signal | Oct 28, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 15, 2025 | 1 year ago |
| RSI: Overbought | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| SMA: Bearish | Aug 26, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| SMA: Bullish | Aug 21, 2025 | 1 year ago |
| SMA: Bearish | Aug 20, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 15, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| SMA: Bearish | Jul 29, 2025 | 1 year ago |
| SMA: Bullish | Jul 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| RSI: Oversold | Jun 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| RSI: Oversold | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 26, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Jan 31, 2025 | 1 year ago |
| SMA: Bullish | Jan 30, 2025 | 1 year ago |
| SMA: Bearish | Jan 22, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 6, 2025 | 1 year ago |
| RSI: Oversold | Nov 25, 2024 | 1 year ago |
Key statistics
- Market cap
- 152.82M
- Enterprise value
- 162.90M
- Trailing P/E
- 0.00
- Forward P/E
- -2.52
- PEG ratio
- 0.00
- Price / sales
- 436.63
- Price / book
- 0.00
- EPS (TTM)
- -2.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 350.00K
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 12.61M
- Total debt
- 10.52M
- Return on equity
- 0.00%
- Shares outstanding
- 20.16M
- Short % of float
- 2.51%
- 50-day average
- 8.46
- 200-day average
- 8.46
Analyst view
Consensus: none
Price target (mean) 19.91 +402.7% upside
Now 3.96
- Target (low)
- 17.00
- Target (mean)
- 19.91
- Target (high)
- 22.63
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Jul 8, 2024
Expected Jul 8, 2024. Consensus EPS estimate -0.91409.
Financials — quick view
CAMP Revenue — quarterly 1.78M
CAMP Net income — quarterly -33.53M
CAMP EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 8, 2024 | May 1, 2024 | -0.92 | — | — | — |
| Jun 6, 2024 | Feb 1, 2024 | -3.22 | — | — | — |
| Jan 9, 2024 | Nov 1, 2023 | -2.30 | — | — | — |
| Oct 5, 2023 | Aug 1, 2023 | 0.46 | — | — | — |
| Jul 10, 2023 | May 1, 2023 | 0.92 | — | — | — |
| Apr 27, 2023 | Feb 1, 2023 | 0.23 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | William Blair | init | — | Outperform |
| Nov 5, 2024 | Leerink Partners | init | — | Outperform |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
| Nov 5, 2024 | Piper Sandler | init | — | Overweight |
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- camp4tx.com
News
- CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
- CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
- Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10
- CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease
- Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
- CAMP4 to Participate in Chardan's 10th Annual Healthcare Conference
- CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Rated “Moderate Buy” by Wall Street Brokerages
- Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
- CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002
Your note
Sign in to keep a note on CAMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM PARTNERS VI, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| AH EQUITY PARTNERS BIO I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| ENAVATE SCIENCES GP, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
| HOLTZMAN STEVEN H | Director | Conversion of Exercise of derivative security | Oct 14, 2024 | 108,946 |
| MANDEL-BREHM JOSH | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 14, 2024 | 272,357 |
| NASHAT AMIR H. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 14, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.13% | 227,300 | 1.72M | Oct 30, 2024 |
| Fidelity Growth Company Fund | 0.85% | 171,200 | 1.30M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.26% | 52,404 | 397.22K | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 0.22% | 43,500 | 329.73K | Oct 30, 2024 |